All In Biotech

Drug Trial Radar · NCT04403100

Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: "The Hope Coalition - 1"

Hydroxychloroquine and Lopinavir/ Ritonavir for Hospitalization and Mortality Reduction in Patients With COVID-19 and Mild Disease Symptoms: "The Hope Coalition"

Last checked: Nov 20, 2026Latest source record: Jan 26, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 1,968 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,968

Planned (sponsor's estimate)

Start

Jun 3, 2020

Primary completion

Feb 1, 2021

Study completion Feb 1, 2021

Sponsor

Lead sponsor
CardresearchAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Cardresearch - Cardiologia Assistencial e de Pesquisa LTDA; Cytel Inc.
First posted
May 27, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The COVID-19 pandemic has been characterized by high morbidity and mortality, especially in certain subgroups of patients. To date, no treatment has been shown to be effective in controlling this disease in hospitalized patients with moderate and / or severe cases of this disease. Hydroxychloroquine and lopinavir / ritonavir have been shown to inhibit SARS-CoV viral replication in experimental severe acute respiratory symptoms models and have similar activity against SARS-CoV2. Although widely used in studies of critically ill patients, to date, no study has demonstrated its role on the treatment of high-risk, newly diagnosed patients with COVID-19 and mild symptoms.

Conditions

  • COVID-19
  • Coronavirus Infection
  • Virus Disease
  • Acute Respiratory Infection
  • SARS-CoV Infection

Interventions

  • Hydroxychloroquine Sulfate TabletsDrug

    Tablets of 400 mg: Loading dose of 02 tablets followed by one tablet of 400 mg orally on the following 09 days

  • Lopinavir/ Ritonavir Oral TabletDrug

    tablets of 200/ 50 mg; Loading dose of 04 tablets twice a day on day 1 followed by two tablets twice a day on the following 09 days

  • Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral TabletsDrug

    Hydroxychloroquine Oral Tablet 400 mg: Loading dose of 02 tablets followed by one tablet of 400 mg orally on the following 09 days plus Lopinavir/ Ritonavir Oral Tablet of 200/ 50 mg: Loading dose of 04 tablets twice a day on day 1 followed by two tablets twice a day on the following 09 days

  • PlaceboDrug

    Placebo tablets - 01 tablet twice daily from day 01 through day 10.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants who were hospitalized for progression of COVID-19 diseaseTime frame: Measuring during 28-day period since randomization (Intention to treat analysis)
  2. Proportion of participants who died due to COVID-19 progression and/ or complicationsTime frame: Measuring during 28-day period since randomization (Intention to treat analysis)

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • CARDRESEARCH - Cardiologia Assistencial e de Pesquisa

    Belo Horizonte, Minas Gerais, Brazil · Recruiting

  • Pontificia Universidade Catolica de Minas Gerais

    Belo Horizonte, Minas Gerais, Brazil · Not yet recruiting

  • Fundo Municipal de Saúde de Betim

    Betim, Minas Gerais, Brazil · Recruiting

  • Universidade Federal de Ouro Preto

    Ouro Preto, Minas Gerais, Brazil · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.